Support & Resources

  • Abeona Assist
  • Strong Together Network
  • Resources
  • ZEVASKYN Qualified
    Treatment Centers
  • Stay Connected
Upper Group

Abeona Assist

Abeona Assist® is here for your patients

A personalized support program providing comprehensive resources

Whether you are exploring ZEVASKYN treatment, have questions, or are ready to take the next steps, contact a Patient Navigator today for more information.

Abeona Assist Patient Navigators* help your patients understand the ZEVASKYN treatment pathway, provide resources, and answer questions

  • ZEVASKYN Treatment Pathway

    Trained Patient Navigators provide information on ZEVASKYN, what to expect, and next steps to take

  • Coverage Review and Financial Assistance†

    The team works to explore patient benefits, identify out-of-pocket costs, and provide information about access and reimbursement

  • Travel and Logistical Support†

    The team helps coordinate travel to a ZEVASKYN Qualified Treatment Center and provides support during the patient’s stay

*Patient Navigators do not direct patient care or provide medical advice.
†Eligibility requirements apply.

call-icon Phone icon

To find a ZEVASKYN Qualified Treatment Center, get your questions answered, and enroll your patients:

Call 1-855-ABEONA-1 (1-855-223-6621)

Monday-Friday
9:00 am-6:30 pm ET

Strong Together Network

Connect your patients to others who have experience with ZEVASKYN treatment with the Strong Together Network‡

  • The Strong Together Network is a group of patients and caregivers who can discuss their personal ZEVASKYN journey in a one-on-one setting with your patients and their loved ones
  • Whether your patients are considering treatment or are ready to start, these conversations with others who understand what they may be going through can be helpful
  • To learn more about the Strong Together Network, contact Abeona Assist at 1-855-ABEONA-1 (1-855-223-6621)
  • ‡Participants must be at least 18 years of age or accompanied by a parent or guardian and reside in the United States. Strong Together Network patients and caregivers do not provide medical advice and only share their personal experiences. Conversations are not meant to take the place of discussions with healthcare providers.
Lara, a ZEVASKYN patient
Lara, a ZEVASKYN patient
Antonio, a ZEVASKYN patient
Antonio, a ZEVASKYN patient
Noelle, a ZEVASKYN patient
Noelle, a ZEVASKYN patient
Suzy, a ZEVASKYN caregiver
Suzy, a ZEVASKYN caregiver
Gus, a ZEVASKYN caregiver
Gus, a ZEVASKYN caregiver

Resources

Additional resources for you and your patients

Discover stories from patients treated with ZEVASKYN, along with insights from caregivers and EB specialists

Access video

Collage of photos of ZEVASKYN patients and caregivers

Help your patients enroll in Abeona Assist to get comprehensive support

Discover support available to your patients or call 1-855-223-6621

Learn about treatment with ZEVASKYN—or share with your colleagues

Download healthcare professional brochure

Healthcare professional brochure for ZEVASKYN

Help your patients with RDEB learn about treatment with ZEVASKYN

Download patient brochure

ZEVASKYN patient brochure
  • EB=epidermolysis bullosa; RDEB=recessive dystrophic epidermolysis bullosa.

ZEVASKYN Qualified Treatment Centers

Refer your patients to ZEVASKYN Qualified Treatment Centers§

ZEVASKYN will be surgically applied to wounds by a dedicated care team at a ZEVASKYN Qualified Treatment Center listed below. Abeona Therapeutics is in the process of partnering with additional ZEVASKYN Qualified Treatment Centers.

Check back soon for more information or call 1-855-ABEONA-1 (1-855-223-6621).

ZEVASKYN Qualified Treatment Centers

Ann & Robert H. Lurie Children's Hospital of Chicago

Chicago, IL 60611

Children's Hospital Colorado

Aurora, CO 80045

Children’s Hospital of Philadelphia (CHOP)

Philadelphia, PA 19104

NewYork-Presbyterian/Columbia University Irving Medical Center

New York, NY 10032

Stanford Medicine Children's Health

Palo Alto, CA 94304

The University of Texas Medical Branch at Galveston

Galveston, TX 77555
  • §ZEVASKYN Qualified Treatment Centers are independently owned and operated. Abeona Therapeutics does not oversee any treatment centers or the medical care they provide.

Early referral to a ZEVASKYN Qualified Treatment Center is critical to confirm patient eligibility and initiate treatment

Wave icon
Noelle, a patient treated with ZEVASKYN, smiling

ZEVASKYN treatment has helped me a lot, like not having open wounds, not having to do bandages, not having to worry about infections in that area, it makes such a difference.”

Find out how ZEVASKYN made a difference for Noelle Right-open Right-open

Stay Connected

Stay in the know about ZEVASKYN treatment

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

By providing your personal information, you acknowledge and agree that it may be shared with Abeona Therapeutics and its third-party partners. Abeona Therapeutics and its service providers will not sell or share your personally identifiable information and will only share it according to the Privacy Policy.

By clicking “Submit,” you consent to receive communications from Abeona Therapeutics and its partners regarding products, services, corporate updates, and promotional offers, in accordance with the Terms and Conditions.

For more details, please review the Privacy Policy.

Discover what healing can look like Right-open Right-open

Indication

ZEVASKYN® (prademagene zamikeracel) is an autologous cell sheet-based gene therapy indicated for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB).

Important Safety Information

  • Severe hypersensitivity reactions to vancomycin, amikacin, or product excipients may occur with ZEVASKYN application. Monitor for signs and symptoms of hypersensitivity reactions such as itching, swelling, hives, difficulty breathing, runny nose, watery eyes, nausea, and in severe cases, anaphylaxis and treat according to standard clinical practice.
  • Retroviral vector (RVV)-mediated insertional oncogenesis may potentially occur after treatment with ZEVASKYN. Monitor patients lifelong after treatment for the development of malignancies. In the event that a malignancy occurs, contact Abeona Therapeutics Inc. at 1-844-888-2236.
  • Transmission of infectious disease or agents may occur with ZEVASKYN because it is manufactured using human- and bovine-derived reagents, which are tested for human and animal viruses, bacteria, fungi, and mycoplasma before use. These measures do not eliminate the risk of transmitting these or other infectious diseases or agents.
  • The most common adverse reactions (incidence ≥5%) were procedural pain and pruritus.

Please see full Prescribing Information.

Indication

ZEVASKYN® (prademagene zamikeracel) is an autologous cell sheet-based gene therapy indicated for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB).

Important Safety Information

  • Severe hypersensitivity reactions to vancomycin, amikacin, or product excipients may occur with ZEVASKYN application. Monitor for signs and symptoms of hypersensitivity reactions such as itching, swelling, hives, difficulty breathing, runny nose, watery eyes, nausea, and in severe cases, anaphylaxis and treat according to standard clinical practice.
  • Retroviral vector (RVV)-mediated insertional oncogenesis may potentially occur after treatment with ZEVASKYN. Monitor patients lifelong after treatment for the development of malignancies. In the event that a malignancy occurs, contact Abeona Therapeutics Inc. at 1-844-888-2236.
  • Transmission of infectious disease or agents may occur with ZEVASKYN because it is manufactured using human- and bovine-derived reagents, which are tested for human and animal viruses, bacteria, fungi, and mycoplasma before use. These measures do not eliminate the risk of transmitting these or other infectious diseases or agents.
  • The most common adverse reactions (incidence ≥5%) were procedural pain and pruritus.

Please see full Prescribing Information.

Abeona Therapeutics® logo

ZEVASKYN, Abeona Assist, and the related logos are trademarks of Abeona Therapeutics Inc. All other trademarks are the property of their respective owners.

© 2025 Abeona Therapeutics Inc. All rights reserved. US-COM-ZEV-240021  11/25